Search Results for “EU” – Page 395 – media

How to Write a Development Letter to Clients after an Exhibition

After attending Shanghai CNEF and Hospitalar in Brazil you come home and look at the pile of name cards and the masses of client information you collected. Now what? We often establish new business relationships at exhibitions such as these but the key of securing them lies in how you follow up on your clients. Ddu (www.drugdu.com), the leading global pharmaceutical and medical device B2B online platform, today shares with you some insight on how to organize client materials and write your first follow up development letter. I. Organize and follow up on your clients with purpose The first step is to collect as much information as possible and pay special attention to all the relevant details at the exhibition. For example, what the client is looking for, what they are most concerned about, what kind of products and suppliers they have in mind and which business partners they would like to keep. After this you will be able to arrange the information according to clients’ interests ...
- Source: Ddu
- 892
- September 18, 2017
Ddu College development letter
China’s Import and Export Report of Surgical Instruments

According to a global statistics report on medical devices, the global surgical instruments market has witnessed a drastic growth spurt in the past 8 years. In 2010, global sales of surgical instruments reached 12 billion USD, 12.9 billion USD in 2011 and 18.6 billion USD in 2014.
- Source: Ddu
- 2,996
- September 15, 2017
export import Market Reports surgical
Medical Trade Exhibitions in September — Global Product Promotions from the Comfort of Your Own Home!

Since the launch of the Ddu Global Promotion Plan, Ddu has succeeded in helping users do international product promotions without leaving home and has matched thousands of orders, rapidly gaining popularity in the medical trade industry. The upcoming exhibitions of Ddu’s Global Promotion Plan include Thailand, Vietnam, Azerbaijan and Argentina!
- Source: Ddu
- 609
- September 15, 2017
Argentina Azerbaijan Exhibitions & Activities Thailand
Boehringer collaborates with Gubra to develop next generation obesity treatments

Germany based Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
- Source: Biospectrumasia
- 486
- September 14, 2017
cardiometabolic Market Views obesity
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD® had revenues of approximately $168 million for the trailing twelve month period ending June 30, 2017. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively.
- Source: finance.yahoo
- 531
- September 13, 2017
Company Insight Market Views oncology PARAGARD
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53%

Novartis today announced results from a Phase III study of 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) .
- Source: Novartis
- 827
- September 13, 2017
Mekinist Phase Tafinlar
Bay Area’s ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene (CELG) And Google (GOOG)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO's lead immunotherapy agent AM0010 in non-small cell lung cancer(NSCLC) and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
- Source: biospace
- 528
- September 13, 2017
immunotherapy Market Views NSCLC pancreatic renal Series
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 557
- September 12, 2017
asthma Clinical Trials dupilumab Phase
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 542
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,273
- September 11, 2017
cancer Company Insight T-cell

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.